Patent Number: 8,822,425

Title: Dosage of oligonucleotides suitable for the treatment of tumors

Abstract: A method for preventing and/or treating a tumor, the method comprising: intravenously administering an antisense oligonucleotide in an amount of between about 400 to about 800 mg/m.sup.2/treatment cycle, the antisense oligonucleotide comprises 8 to 30 nucleotide building blocks, which hybridizes with mRNA of TGF-beta-2, -1 and/or -3 for the preparation of a pharmaceutical composition.

Inventors: Schlingensiepen; Karl-Hermann (Donaustauf, DE), Heinrichs; Hubert (Regensburg, DE), Schmaus; Susanne (Grossberg-Pentling, DE)

Assignee: Antisense Pharma GmbH

International Classification: C12N 15/11 (20060101); C07H 21/04 (20060101)

Expiration Date: 9/02/12018